Pharmaceutical compositions comprising sphingosine-1-phosphate receptor agonists having controlled particle size

The present invention relates to a pharmaceutical composition comprising a sphingosine-1-phosphate receptor agonist having a controlled particle size, and more specifically, to a pharmaceutical composition comprising: 1-[1-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3, 3, 4-triazole-1-yl]-1-(3-chloro-6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-1, 3, 4-triazole-1-yl)-1, 3, 4-triazole-1-yl)-1, 3, 4-triazole-1-yl)-1, 3, 4-triazole-1-yl)-1, 3, 4- The present invention relates to a pharmaceutical composition comprising a compound of [1, 2, 4-dihydro-naphthalene-2-ylmethyl]-piperidine-4-formic acid or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the particle size d (0.9) of the active ingredient is 60 [mu] m or less. 本发明涉及一种药物组合物，所述药物组合物包含具有受控粒度的鞘氨醇-1-磷酸酯受体激动剂，更具体地，涉及一种药物组合物，所述药物组合物包含：作为活性成分的化学式1的1-[1-氯-6-(3-氯-1-异丙基-1H-吲唑-5-基甲氧基)-3,4-二氢-萘-2-基甲基]-哌啶-4-甲酸或其药学上可接受的盐；以及药学上可接受的载体，其中所述活性成分的粒度d(0.9)为60μm以下。